Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 [Yahoo! Finance]
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Valneva SE (INRLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved ... [Yahoo! Finance]
Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates